ライフサイエンスコーパス: adenomatous polyposis

1 is associated with pathogenesis of familial adenomatous polyposis.

2 ng causes of death in patients with familial adenomatous polyposis.

3 t with Apc, are important models of familial adenomatous polyposis.

4 a development in an animal model of familial adenomatous polyposis.

5 n combination in an animal model of familial adenomatous polyposis.

6 mice provide a good model of human familial adenomatous polyposis.

7 n additional recessive subtype of colorectal adenomatous polyposis.

8 pathogenic variants associated with familial adenomatous polyposis.

9 m 102 unrelated individuals with unexplained adenomatous polyposis.

10 equently remains unresolved in patients with adenomatous polyposis.

11 sies from IPAA patients with UC and familial adenomatous polyposis.

12 ch are similar to those observed in familial adenomatous polyposis.

13 is (chronic ulcerative colitis 97%, familial adenomatous polyposis 3%) and previous operative history

14 es of hereditary syndromes, such as familial adenomatous polyposis, a cancer predisposition syndrome

15 Patients with familial adenomatous polyposis after pouch surgery (n = 9), indiv

16 rome and the phenotypic features of familial adenomatous polyposis aid significantly in syndrome diag

17 , germline mutation of which causes familial adenomatous polyposis, an autosomal intestinal cancer sy

18 Germline mutations cause familial adenomatous polyposis and at least two-thirds of sporadi

19 edisposes to a new subtype of BER-associated adenomatous polyposis and CRC.

20 types in a murine model of colon cancer, the adenomatous polyposis (APC) mutant (Apc (716/+)) model.

21 in animals and in patients with the familial adenomatous polyposis by downregulating beta-catenin sig

22 The adenomatous polyposis cell (APC) tumor suppressor is a m

23 e conditionally expressed a mutant allele of adenomatous polyposis coli (APC(cKO)) in murine uterine

24 n on chronic hypoxia-induced PH, we used the adenomatous polyposis coli (Apc(Min/+)) mouse, where red

25 The tumor suppressor Adenomatous polyposis coli (APC) affects the function of

26 induced by the rare inheritance of a mutant adenomatous polyposis coli (Apc) allele.

27 ministering LPA to mice heterozygous for the adenomatous polyposis coli (Apc) allele.

28 contribution of the Wnt-regulating proteins adenomatous polyposis coli (APC) and APC2 in the pathoge

29 ested that specific GSK3 substrates, such as adenomatous polyposis coli (APC) and collapsin response

30 we show that two tumor suppressor proteins, adenomatous polyposis coli (APC) and Dlg1-SAP97, are req

31 wo microtubule plus end-associated proteins, adenomatous polyposis coli (APC) and EB1, providing a po

32 onal and transcriptional mechanisms and that adenomatous polyposis coli (APC) and GSK3beta, which are

33 expression of the gut tumor suppressor gene adenomatous polyposis coli (Apc) and its role in the oli

34 Finally, CBC stem cells deficient in adenomatous polyposis coli (Apc) and Math1 were able to

35 ed by the colorectal cancer tumor suppressor adenomatous polyposis coli (APC) and that KLF4 repressed

36 ther, we find that both the tumor suppressor adenomatous polyposis coli (APC) and the ADP-ribose poly

37 nce microscopy to image the tumor suppressor adenomatous polyposis coli (APC) and the formin mDia1 du

38 firmed an expected loss in the expression of adenomatous polyposis coli (APC) and the transcriptional

39 First, patients with germline mutations in adenomatous polyposis coli (APC) are susceptible to stom

40 polyposis (FAP) but further study identified adenomatous polyposis coli (APC) as responsible for FAP

41 Here we find that the tumor suppressor adenomatous polyposis coli (APC) controls microtubule ta

42 C57BL/6J mice carrying the Min allele of Adenomatous polyposis coli (Apc) develop numerous adenom

43 Mutations in adenomatous polyposis coli (APC) disrupt regulation of W

44 rectal cancers consistently contained mutant adenomatous polyposis coli (APC) DNA molecules in their

45 As Adenomatous Polyposis Coli (APC) functions in many of th

46 mice bearing a heterozygote mutation in the adenomatous polyposis coli (APC) gene (Apc(Min/+) mice).

47 ted gene-targeted pigs with mutations in the adenomatous polyposis coli (APC) gene (APC) that are ort

48 The adenomatous polyposis coli (Apc) gene also plays an impo

49 of these models involve modification of the adenomatous polyposis coli (Apc) gene and are excellent

50 ased in human cells with deficiencies in the adenomatous polyposis coli (APC) gene and in cells stimu

51 We show that a deficiency in the adenomatous polyposis coli (APC) gene and subsequent act

52 Mutations in the adenomatous polyposis coli (APC) gene are associated wit

53 Patients with mutations in the Adenomatous Polyposis Coli (APC) gene are at increased r

54 Somatic mutations of the adenomatous polyposis coli (APC) gene are initiating eve

55 Mutations in the adenomatous polyposis coli (APC) gene are pivotal in col

56 Mutations in the human adenomatous polyposis coli (APC) gene are thought to ini

57 l cancer cell lines bearing mutations on the adenomatous polyposis coli (APC) gene as a model of FAP-

58 The adenomatous polyposis coli (APC) gene encodes APC tumour

59 Since the Adenomatous Polyposis Coli (APC) gene is mutated in the

60 The Adenomatous Polyposis Coli (APC) gene is mutated in the

61 Although beta-catenin and adenomatous polyposis coli (APC) gene mutations are well

62 Adenomatous polyposis coli (APC) gene mutations have bee

63 Mutations in the adenomatous polyposis coli (APC) gene occur in the vast

64 ost colorectal cancers have mutations of the adenomatous polyposis coli (APC) gene or the beta-cateni

65 The adenomatous polyposis coli (APC) gene product is mutated

66 letion in mice with inactivating mutation of adenomatous polyposis coli (APC) gene reduces intestinal

67 Mutations in the adenomatous polyposis coli (APC) gene result in uncontro

68 ssf1a can cooperate with inactivation of the adenomatous polyposis coli (Apc) gene to accelerate inte

69 ization of beta-catenin or defective for the adenomatous polyposis coli (APC) gene to reinvestigated

70 n the bladder as conditional deletion of the adenomatous polyposis coli (Apc) gene within the adult b

71 intestinal carcinogenesis is mutation of the adenomatous polyposis coli (APC) gene, which leads to ac

72 requently bear inactivating mutations of the adenomatous polyposis coli (APC) gene, whose product is

73 velop through loss of normal function of the Adenomatous polyposis coli (APC) gene.

74 g, in particular, tumor suppressors TP53 and adenomatous polyposis coli (APC) gene.

75 imiting mutations in human CRC occurs in the adenomatous polyposis coli (APC) gene.

76 omas had somatic truncation mutations to the adenomatous polyposis coli (Apc) gene.

77 nt in mice with heterozygous mutation in the adenomatous polyposis coli (APC) gene.

78 ontinues to be dominated by mutations in the adenomatous polyposis coli (APC) gene.

79 e generated mice lacking the beta-catenin or adenomatous polyposis coli (Apc) genes in osteoblasts.

80 Wnt/beta-catenin pathway signaling following adenomatous polyposis coli (APC) inactivation.

81 Mutations in the tumor suppressor adenomatous polyposis coli (APC) initiate most colon can

82 The tumor suppressor adenomatous polyposis coli (APC) is a crucial regulator

83 ncluding the brain, and the tumor suppressor adenomatous polyposis coli (APC) is a key negative regul

84 Adenomatous polyposis coli (APC) is a large multidomain

85 Adenomatous polyposis coli (APC) is a microtubule plus-e

86 The tumor suppressor Adenomatous polyposis coli (APC) is a negative regulator

87 Mutational inactivation of adenomatous polyposis coli (APC) is an early event in co

88 The tumor suppressor adenomatous polyposis coli (APC) is an essential negativ

89 The tumor suppressor adenomatous polyposis coli (APC) is an essential negativ

90 ASE of adenomatous polyposis coli (APC) is associated with path

91 Adenomatous polyposis coli (APC) is best known for its c

92 Mutation of the tumor suppressor adenomatous polyposis coli (APC) is considered an initia

93 The tumor suppressor adenomatous polyposis coli (APC) is implicated in regula

94 The tumor suppressor protein adenomatous polyposis coli (APC) is multifunctional - it

95 Adenomatous polyposis coli (APC) is mutated in colon can

96 Adenomatous polyposis coli (APC) is one such MAP with a

97 Loss of tumor suppressor adenomatous polyposis coli (APC) is thought to initiate

98 aling following loss of the tumor suppressor adenomatous polyposis coli (APC) is thought to initiate

99 ore, the loss of heterozygosity rates at the adenomatous polyposis coli (Apc) locus are unaffected by

100 Today, the tumor suppressor adenomatous polyposis coli (APC) may have the same compl

101 Here, we show that adenomatous polyposis coli (APC) modulates microtubule (

102 esis that initiation of colorectal cancer by adenomatous polyposis coli (APC) mutation is mediated by

103 Adenomatous polyposis coli (APC) mutation is the most co

104 Adenomatous polyposis coli (APC) mutations are linked to

105 In this study, we show that adenomatous polyposis coli (APC) mutations found in huma

106 nt/beta-catenin pathway activation caused by adenomatous polyposis coli (APC) mutations occurs in app

107 The tumor suppressor Adenomatous polyposis coli (APC) negatively regulates Wn

108 (CRCs), an initiating mutation occurs in the adenomatous polyposis coli (APC) or beta-catenin gene, a

109 n that have been associated with loss of the adenomatous polyposis coli (APC) or constitutive activat

110 d glycogen synthase kinase 3beta (GSK-3beta)/adenomatous polyposis coli (APC) pathways.

111 Adenomatous polyposis coli (APC) plays a critical role i

112 The tumor suppressor Adenomatous polyposis coli (APC) plays a key role in reg

113 nestin expressing NeuN positive neurons and adenomatous polyposis coli (APC) positive mature oligode

114 In interphase cells, the adenomatous polyposis coli (APC) protein accumulates on

115 ibition of GSK-3beta and accumulation of the adenomatous polyposis coli (APC) protein at the plus end

116 ere, we report that the expression status of adenomatous polyposis coli (APC) protein determines the

117 The adenomatous polyposis coli (APC) protein functions as a

118 Loss of the adenomatous polyposis coli (APC) protein is a common ini

119 Adenomatous polyposis coli (APC) protein is a large tumo

120 CtBP interacts with adenomatous polyposis coli (APC) protein, and is stabili

121 Fap1 also interacts with the adenomatous polyposis coli (Apc) protein, but the functi

122 inked to deficiencies in mismatch repair and adenomatous polyposis coli (APC) proteins, diet, inflamm

123 ing a knockout allele in the gatekeeper gene Adenomatous polyposis coli (Apc) recapitulates familial

124 The tumor suppressor protein adenomatous polyposis coli (APC) regulates cell protrusi

125 Adenomatous polyposis coli (APC) regulates the activity

126 is functionally important for cell migration.Adenomatous polyposis coli (APC) regulates the localizat

127 gene targeting in mice, we demonstrate that adenomatous polyposis coli (APC) serves an essential fun

128 ne such pathway the tumor-suppressor protein adenomatous polyposis coli (APC) targets RNAs to cell pr

129 Here, we have defined a repeat sequence in adenomatous polyposis coli (APC) that binds to EB1's COO

130 ting factor-responsive cells were defined by adenomatous polyposis coli (APC) time-of-flight mass cyt

131 Binding of adenomatous polyposis coli (APC) to the microtubule plus

132 In turn, KIF17 participates in localizing adenomatous polyposis coli (APC) to the plus ends of a s

133 The adenomatous polyposis coli (APC) tumor suppressor forms

134 Acquired or inherited mutations in the adenomatous polyposis coli (APC) tumor suppressor gene a

135 The adenomatous polyposis coli (APC) tumor suppressor gene e

136 The Adenomatous Polyposis Coli (APC) tumor suppressor gene i

137 Mutations in the adenomatous polyposis coli (APC) tumor suppressor gene i

138 Mutations in the adenomatous polyposis coli (APC) tumor suppressor gene s

139 found in patients harboring mutations in the adenomatous polyposis coli (APC) tumor suppressor gene.

140 Inactivation of the adenomatous polyposis coli (APC) tumor suppressor is fre

141 The adenomatous polyposis coli (APC) tumor suppressor is ina

142 The adenomatous polyposis coli (Apc) tumor suppressor is inv

143 ce with IEC-specific allelic deletion of the adenomatous polyposis coli (Apc) tumor suppressor locus,

144 atase 2A (PP2A) and must be protected by the adenomatous polyposis coli (APC) tumor suppressor protei

145 Mutation of the adenomatous polyposis coli (APC) tumor suppressor stabil

146 rcinomas contain truncating mutations in the adenomatous polyposis coli (APC) tumor suppressor, a neg

147 in signaling is negatively controlled by the adenomatous polyposis coli (APC) tumor suppressor, which

148 calculating the in vivo mutation rate of the adenomatous polyposis coli (APC) tumor-suppressor gene i

149 ollows a genetic pathway whereby loss of the adenomatous polyposis coli (APC) tumour suppressor and a

150 RNAs in the granules associate with the adenomatous polyposis coli (APC) tumour suppressor and t

151 Mutations in the adenomatous polyposis coli (APC) tumour suppressor are t

152 Mutations in Adenomatous polyposis coli (APC) underlie familial adeno

153 Mutations in adenomatous polyposis coli (APC) underlie the earliest s

154 In this study, the tumor suppressor protein adenomatous polyposis coli (APC) was found to be importa

155 We found that the tumor suppressor adenomatous polyposis coli (APC) was required for microt

156 These mice were crossed with adenomatous polyposis coli (Apc)(min/+) mice, or given a

157 ne the genetic relationship between MPC1 and Adenomatous polyposis coli (APC), a key tumor suppressor

158 Inactivating mutations within adenomatous polyposis coli (APC), a negative regulator o

159 approaches suggest that the tumor suppressor adenomatous polyposis coli (APC), a regulator of Wnt sig

160 Adenomatous polyposis coli (APC), a tumor suppressor com

161 Adenomatous polyposis coli (Apc), a tumor suppressor gen

162 Adenomatous polyposis coli (APC), a tumor suppressor gen

163 Specific site of CpG islands of adenomatous polyposis coli (APC), a well studied tumor s

164 The tumor suppressor adenomatous polyposis coli (APC), an essential negative

165 atenin destruction complex components Axin1, adenomatous polyposis coli (APC), and GSK3beta were also

166 ein complex containing the proteins axin and adenomatous polyposis coli (APC), both of which bind dir

167 forms a complex with axin (axis inhibitor), adenomatous polyposis coli (APC), casein kinase 1alpha (

168 Rac1-specific exchange factor stimulated by adenomatous polyposis coli (APC), contributing to colore

169 Together with its direct binding partner adenomatous polyposis coli (APC), EB1 can stabilize micr

170 Mutations in known driver genes [e.g., adenomatous polyposis coli (APC), KRAS, or PIK3CA] found

171 Individual crypt adenomatous polyposis coli (APC), p53, K-RAS, and 17p lo

172 in acromegaly patients induced colon p53 and adenomatous polyposis coli (APC), reversing progrowth GH

173 e designed against beta-catenin (Ctnnb1) and adenomatous polyposis coli (Apc), two commonly mutated g

174 ical Wnt signaling by targeting the gene for Adenomatous Polyposis Coli (Apc), which controls Wnt sig

175 e, we show that the tumor suppressor protein adenomatous polyposis coli (APC), which is a known MT-as

176 eracts with beta-catenin through a conserved adenomatous polyposis coli (APC)-like domain.

177 Expression of eIF6 in adenomatous polyposis coli (APC)-mutant colon cancer cel

178 o develop colitis-associated and spontaneous adenomatous polyposis coli (APC)-related tumors of the i

179 P), Skp1, transducin beta-like 1 (TBL1), and adenomatous polyposis coli (APC).

180 runcating mutations in the tumor suppressor, adenomatous polyposis coli (APC).

181 glycogen synthase kinase-3beta, axin-1, and adenomatous polyposis coli (APC).

182 to the inactivation of the tumor suppressor adenomatous polyposis coli (APC).

183 by aberrant function of the tumor suppressor Adenomatous polyposis coli (Apc).

184 ation suppresses beta-catenin activity in an adenomatous polyposis coli (APC)/glycogen synthase kinas

185 s; and suppresses colonic polyp formation in adenomatous polyposis coli (APC)min/+ mice.

186 We analyzed adenomatous polyposis coli (Apc)min/+/Sigirr-/- mice for

187 Arm is targeted for proteolysis by the Axin/Adenomatous polyposis coli (Apc1 and Apc2)/Zeste-white 3

188 V integration site family (WNT)/beta-catenin/adenomatous polyposis coli (CTNNB1/APC) pathway has been

189 In addition we identified adenomatous polyposis coli 1 (APC1) as an interaction pa

190 Germline specific overexpression of Adenomatous Polyposis Coli 2 (APC2) rescued GSC loss in

191 sly in germ cells for proper localization of Adenomatous polyposis coli 2 and E-cadherin at the hub-G

192 vilVEGF1 mice were bred to Min mice (adenomatous polyposis coli [APC] +/-).

193 ation of the centrosomal proteins Ninein and adenomatous polyposis coli abolished this bias.

194 tive regulators of beta-catenin, such as the adenomatous polyposis coli and Axin tumor suppressor pro

195 G-protein signaling (RGS) domain that binds adenomatous polyposis coli and Galpha subunits, thereby

196 atenin and the destruction complex component adenomatous polyposis coli at a similar SLS motif to the

197 as associated with reduced expression of the adenomatous polyposis coli gene (APC).

198 iation domain family 1 gene RASSF1A, and the adenomatous polyposis coli gene APC in tumors and in his

199 Mice carrying and non-sense mutation in Adenomatous polyposis coli gene at site R850, which desi

200 eta-catenin by inhibiting its binding to the adenomatous polyposis coli gene product and subsequent g

201 eficient mice carrying the Min allele of the adenomatous polyposis coli gene.

202 and compared to control mice carry wildtype Adenomatous polyposis coli gene.

203 t is caused by inactivating mutations in the Adenomatous polyposis coli gene.

204 Crossing Tfam(+/-) mice to the adenomatous polyposis coli multiple intestinal neoplasia

205 Here, we demonstrate that adenomatous polyposis coli mutant APC(Min/+) mice, which

206 RC) harboring functional mutations in either adenomatous polyposis coli or beta-catenin.

207 ling induced by loss of the tumor suppressor adenomatous polyposis coli or casein kinase 1alpha uncov

208 Most information about the roles of the adenomatous polyposis coli protein (APC) and its binding

209 at RNAi-mediated depletion of two kMAPs, the adenomatous polyposis coli protein (APC) and its binding

210 We recently identified adenomatous polyposis coli protein (APC) as a key regula

211 Here we report that the tumour suppressor adenomatous polyposis coli protein (APC) directs the loc

212 We propose that adenomatous polyposis coli protein (APC) is a key coordi

213 n from Mlp of a region similar to one in the adenomatous polyposis coli protein involved in EB1 bindi

214 ows that the actin-nucleating ability of the adenomatous polyposis coli protein is required for disas

215 versely, RNAi of the beta-catenin antagonist adenomatous polyposis coli results in the regeneration o

216 W480 cells stably transformed with wild-type adenomatous polyposis coli showed decreased beta-catenin

217 on, and beta-catenin, a component of the Wnt-adenomatous polyposis coli signaling pathway, contribute

218 syndrome caused by germline mutations in the adenomatous polyposis coli tumor suppressor gene.

219 he microtubule motor cytoplasmic dynein, the adenomatous polyposis coli tumor suppressor protein (APC

220 The APC gene encodes the adenomatous polyposis coli tumour suppressor protein, ge

221 However, little is known about adenomatous polyposis coli's (APC's) role in the mammali

222 member 1, insulin-like growth factor 2, and adenomatous polyposis coli) and other solid tumors (e.g.

223 In the context of APC (adenomatous polyposis coli) deficiency (Apc(Min/+) mice)

224 g in T cell lineages by deletion of the Apc (adenomatous polyposis coli) gene causes spontaneous T ce

225 mutation of the Wnt repressor APC (encoding adenomatous polyposis coli) leads to a state of aberrant

226 that contained mutations in either the APC (adenomatous polyposis coli) locus or in an allele of bet

227 We had shown that the APC (adenomatous polyposis coli) protein controls localizatio

228 Disruption of Apc (adenomatous polyposis coli) within hepatocytes activates

229 ectly targets the tumor suppressor gene APC (adenomatous polyposis coli), thereby affecting Wnt (Wing

230 ducin repeat-containing protein 2), and APC (adenomatous polyposis coli).

231 aditionally attributed to mutations in Axin, adenomatous polyposis coli, and beta-catenin that lead t

232 I, IGF2; tumor suppressor candidate 33, N33; adenomatous polyposis coli, APC; mut-L homolog 1, MLH1;

233 a-catenin pathway mutations, such as loss of adenomatous polyposis coli, are insensitive to this nove

234 Because mutations in adenomatous polyposis coli, beta-catenin and other compo

235 -catenin pathway regulatory genes, including adenomatous polyposis coli, GSK3beta, axin 1, beta-caten

236 Inactivation of the tumor suppressor adenomatous polyposis coli, with the resultant activatio

237 e glycogen synthase kinase 3beta (GSK3beta)- adenomatous polyposis coli-axin-mediated degradation pat

238 otubule organization and capture dynamics in adenomatous polyposis coli-deficient radial progenitors.

239 ted signaling and glycogen synthase kinase-3/adenomatous polyposis coli-mediated beta-catenin activat

240 ence in normal intestinal homeostasis and in adenomatous polyposis coli-mediated tumorigenesis.

241 ng glycogen synthase kinase 3beta, axin, and adenomatous polyposis coli.

242 intestinal tumors driven by mutations in the adenomatous polyposis coli/beta-catenin pathway and acti

243 f cell lines even harboring mutations in the adenomatous polyposis coli/beta-catenin pathway.

244 ble in cell lines harboring mutations in the adenomatous polyposis coli/beta-catenin pathway.

245 erived WNT2 activated canonical signaling in adenomatous polyposis coli/beta-catenin wild-type colon

246 denomas taken from individuals with familial adenomatous polyposis contain high levels of CtBP1 prote

247 edisposing to colorectal cancer are familial adenomatous polyposis (FAP) and hereditary nonpolyposis

248 ications of MMVTx for patients with familial adenomatous polyposis (FAP) and the technical feasibilit

249 Patients with familial adenomatous polyposis (FAP) are at markedly increased ri

250 amatically altered for the worse in familial adenomatous polyposis (FAP) because these patients harbo

251 We studied patients with Familial Adenomatous Polyposis (FAP) because they are virtually c

252 identified as a candidate gene for familial adenomatous polyposis (FAP) but further study identified

253 tumors often occur in patients with familial adenomatous polyposis (FAP) coli who have germ line muta

254 rative colitis (UC) in 37 patients, familial adenomatous polyposis (FAP) in 12 patients, and colonic

255 of thyroid cancer in patients with Familial adenomatous polyposis (FAP) in a prospective study of th

256 Familial adenomatous polyposis (FAP) is a human cancer syndrome c

257 Familial Adenomatous Polyposis (FAP) is characterized by marked u

258 ial cancer predispositions known as familial adenomatous polyposis (FAP) or Gardner syndrome.

259 n colonic and duodenal tumours from familial adenomatous polyposis (FAP) patients has shown that the

260 rliest colonic tissue alteration in familial adenomatous polyposis (FAP) patients, we present the hyp

261 s after 4-6 months of treatment for familial adenomatous polyposis (FAP) patients.

262 ine mutation of which characterizes familial adenomatous polyposis (FAP), an autosomal intestinal can

263 atous polyposis coli (APC) underlie familial adenomatous polyposis (FAP), an inherited cancer syndrom

264 ive colitis, indeterminate colitis, familial adenomatous polyposis (FAP), and a select group of patie

265 inherited predisposition, including familial adenomatous polyposis (FAP), hereditary nonpolyposis col

266 atorial chemoprevention efficacy in familial adenomatous polyposis (FAP), signal of benefit from imag

267 hallmark of many cancers, including familial adenomatous polyposis (FAP)-related desmoid tumors.

268 colorectal polyps in children with familial adenomatous polyposis (FAP).

269 gous to those responsible for human familial adenomatous polyposis (FAP).

270 olorectal adenomas in patients with familial adenomatous polyposis (FAP).

271 oter 1B occur in rare families with familial adenomatous polyposis (FAP).

272 ccur in up to 21 % of patients with Familial Adenomatous Polyposis (FAP).

273 type 2 (MEN2), Cowden syndrome, and familial adenomatous polyposis (FAP).

274 to iPSCs derived from patients with familial adenomatous polyposis (FAP-iPSCs) harboring germline mut

275 nonpolyposis colorectal cancer and familial adenomatous polyposis has provided insight into some of

276 rosis, Duchenne Muscular Dystrophy, Familial Adenomatous Polyposis, Hereditary Non-polyposis Colorect

277 h as multiple endocrine neoplasias, familial adenomatous polyposis, hereditary nonpolyposis colon can

278 ive colitis in 73% of the cases and familial adenomatous polyposis in 17%.

279 sporadic colorectal carcinomas and familial adenomatous polyposis, in 18 sporadic HPs from patients

280 enomas recovered from patients with familial adenomatous polyposis, including adenomas as small as a

281 Familial adenomatous polyposis is an inherited genetic disease, w

282 and multiple POFLs associated with familial adenomatous polyposis is reviewed.

283 yndromes, including Lynch syndrome, familial adenomatous polyposis, MUTYH-associated polyposis, and c

284 testinal tissues from patients with familial adenomatous polyposis (n = 18) or sessile serrated adeno

285 ately 30% of families affected by colorectal adenomatous polyposis, no germline mutations have been i

286 inically from cases with attenuated familial adenomatous polyposis or MUTYH-associated polyposis.

287 A diagnosis of Lynch syndrome, familial adenomatous polyposis, or another genetic syndrome can i

288 osely simulates that found in human familial adenomatous polyposis patients.

289 families showed recessive inheritance of the adenomatous polyposis phenotype and progression to CRC i

290 opic expression of APC, but not its familial adenomatous polyposis-related truncation mutant, promine

291 In murine models of familial adenomatous polyposis, specifically the multiple intesti

292 Studies of tumors from human familial adenomatous polyposis, sporadic colon cancer, and mouse

293 enomas in animals and patients with familial adenomatous polyposis suggest that COX-2 inhibitors may

294 In this study, using a human familial adenomatous polyposis syndrome susceptible mouse model,

295 y nonpolyposis colorectal cancer or familial adenomatous polyposis syndromes.

296 ajority of the 30% of patients with familial adenomatous polyposis that do not test positive for muta

297 diseases, three females (1.6 %) had familial adenomatous polyposis; three patients (1 male and two fe

298 on-negative Lynch syndrome, 16 with familial adenomatous polyposis, two with constitutional mismatch

299 polyposis coli (APC) gene reduces intestinal adenomatous polyposis via Axin/beta-catenin axis and the

300 rom a 16-year-old male patient with familial adenomatous polyposis was insufflated, submerged in a co